Reset
Showing 2 of 2 academic articles

Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era

Luyao Zhang, Jianwen Zhou, Yanyan Sun, Yaodong Zhang et al. • Discover Oncology (2026)

Abstract Background Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of P...

DOAJ Open Access (DOAJ) DOI: 10.1007/s12672-026-05022-z

Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report

Lars Kurch, Thomas W. Georgi, Astrid Monecke, Daniel Seehofer et al. • Frontiers in Oncology (2022)

A 28-year-old female patient with active and difficult-to-treat systemic lupus erythematosus (SLE) was diagnosed with liver-dominant diffused large B-cell lymphoma. Repeated response 18F-FDG-PET studies showed persistently high, and, despit...

DOAJ Open Access (DOAJ) DOI: 10.3389/fonc.2021.798757